Tyrosine Kinase Inhibitors as Reversal Agents for ABC Transporter Mediated Drug Resistance

被引：112

作者：

Anreddy, Nagaraju ^{[1
]}

Gupta, Pranav ^{[1
]}

Kathawala, Rishil J. ^{[1
]}

Patel, Atish ^{[1
]}

Wurpel, John N. D. ^{[1
]}

Chen, Zhe-Sheng ^{[1
]}

机构：

[1] St Johns Univ, Dept Pharmaceut Sci, Coll Pharm & Hlth Sci, Queens, NY 11439 USA

来源：

MOLECULES | 2014年 / 19卷 / 09期

关键词：

tyrosine kinase inhibitors; ABC transporters; chemotherapy; modulators; multidrug resistance; BINDING CASSETTE TRANSPORTER; 2-MEDIATED MULTIDRUG-RESISTANCE; HIGH-AFFINITY INTERACTION; CHRONIC MYELOID-LEUKEMIA; GROWTH-FACTOR RECEPTOR; SUBFAMILY-B MEMBER-1; P-GLYCOPROTEIN ABCB1; CELL LUNG-CANCER; ATP-BINDING; IMATINIB MESYLATE;

D O I：

10.3390/molecules190913848

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

070307 [化学生物学]; 071010 [生物化学与分子生物学];

摘要：

Tyrosine kinases (TKs) play an important role in pathways that regulate cancer cell proliferation, apoptosis, angiogenesis and metastasis. Aberrant activity of TKs has been implicated in several types of cancers. In recent years, tyrosine kinase inhibitors (TKIs) have been developed to interfere with the activity of deregulated kinases. These TKIs are remarkably effective in the treatment of various human cancers including head and neck, gastric, prostate and breast cancer and several types of leukemia. However, these TKIs are transported out of the cell by ATP-binding cassette (ABC) transporters, resulting in development of a characteristic drug resistance phenotype in cancer patients. Interestingly, some of these TKIs also inhibit the ABC transporter mediated multi drug resistance (MDR) thereby; enhancing the efficacy of conventional chemotherapeutic drugs. This review discusses the clinically relevant TKIs and their interaction with ABC drug transporters in modulating MDR.

引用

页码：13848 / 13877

页数：30

共 157 条

[1]

Distribution of Gefitinib to the Brain Is Limited by P-glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2)-Mediated Active Efflux [J].